← Browse by Condition
Medical Condition
triple negative breast cancer
Total Trials
17
Recruiting Now
17
Trial Phases
Phase 2, Phase 1, Phase 3
NCT06291064 Phase 2
Recruiting
Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer
Enrollment
85 pts
Location
Nigeria
Sponsor
University of Chicago
NCT04427293 Phase 1
Recruiting
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
Enrollment
12 pts
Location
United States
Sponsor
University of Illinois at Chic...
NCT05076760 Phase 1
Recruiting
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Enrollment
40 pts
Location
United States
Sponsor
Memgen, Inc.
NCT04468061 Phase 2
Recruiting
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Enrollment
110 pts
Location
United States
Sponsor
Dana-Farber Cancer Institute
NCT06081244 Phase 3
Recruiting
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
Enrollment
348 pts
Location
Germany
Sponsor
West German Study Group
NCT05633654 Phase 3
Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Enrollment
1,514 pts
Location
United States, Austr...
Sponsor
Gilead Sciences
NCT07261631 Phase 1
Recruiting
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Enrollment
180 pts
Location
Canada, France, Isra...
Sponsor
Novartis Pharmaceuticals
NCT05916755
Recruiting
Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform
Enrollment
100 pts
Location
Spain
Sponsor
Vall d'Hebron Institute of Onc...
NCT07281976 Phase 1, Phase 2
Recruiting
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
Enrollment
220 pts
Location
China
Sponsor
Nanjing Leads Biolabs Co.,Ltd
NCT06538896 Phase 2
Recruiting
Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study
Enrollment
20 pts
Location
China
Sponsor
Zhejiang Cancer Hospital
NCT04282044 Phase 1
Recruiting
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Enrollment
60 pts
Location
United States
Sponsor
BioEclipse Therapeutics
NCT05763992 Phase 2
Recruiting
Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial
Enrollment
145 pts
Location
Italy
Sponsor
Fondazione IRCCS Istituto Nazi...
NCT04722978 Phase 3
Recruiting
Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer
Enrollment
228 pts
Location
China
Sponsor
Sun Yat-Sen University Cancer ...
NCT04585750 Phase 1, Phase 2
Recruiting
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Enrollment
300 pts
Location
United States, Austr...
Sponsor
PMV Pharmaceuticals, Inc
NCT05627960 Phase 1
Recruiting
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
Enrollment
77 pts
Location
United States
Sponsor
A&G Pharmaceutical Inc.
NCT06533384 Phase 3
Recruiting
PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC
Enrollment
310 pts
Location
China
Sponsor
Guangdong Provincial People's ...
NCT06393374 Phase 3
Recruiting
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Enrollment
1,530 pts
Location
United States, Argen...
Sponsor
Merck Sharp & Dohme LLC